This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
New Zealand shares rose, led higher by Comvita and Kathmandu Holdings, while Fisher and Paykel Healthcare Corp and Trade Me Group fell.
KTHDY TME TRMEF AIR ZNRGF ZEL ANZFY AIZ FTRRF KMD SKT ZNZ SYKWF THL ANZLY TME SKKTY ANZFF TDMEY KMD
New Zealand shares dropped as heightened global trade tensions weighed across Asian equity markets, led lower by Pushpay Holdings and Trade Me Group while Kathmandu Holdings gained again following its upgrade yesterday.
KTHDY TME GNE TRMEF PPSHY TME GNE TDMEY KMD MEZ GEL KMD
Trade Me Group chief executive Jon Macdonald intends to step away from the company that operates New Zealand's top online marketplace in about six months, leaving a position he held for more than a decade and a company he joined in 2003.
TME TRMEF TME TDMEY
New Zealand shares rose, joining a regional rally, as investors predict whether an upcoming MSCI index review will spur major activity next week. Fletcher Building, which could exit the index, gains, while new addition a2 Milk Co fell.
CEN TME TRMEF PYIYY AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ KMD COENF TME CEN KMD KTHDY AIA FBU WBC SPKKY NZTCY SPK WEBNF WBK FRCEF COENY AIA WBC FBU ANZLY MPP MTPGF ANZFF TDMEY MEZ PFI
New Zealand shares were mixed in light trading ahead of tomorrow's public holiday, with A2 Milk Co and Synlait Milk continuing to weaken while Fisher and Paykel Healthcare Corp rebounded and Fletcher Building extended gains.
TME TRMEF FBU FCREY ZNRGF FRCEF ZEL ZNZ GNE FBU TME GNE TDMEY GEL SML
New Zealand shares gained as the US earnings season helped lift sentiment toward equities. Growth-linked companies including Synlait Milk, A2 Milk, Comvita led gains in the local market.
TME TRMEF FBU RHCGF FCREY MS.PRE MS.PRF MS.PRG RYM MS.PRA FRCEF MS.PRI FBU MS.PRK TME RYHTY TDMEY MS SML
New Zealand shares rose as the local bourse joined a region-wide rally on optimism the US and China will manage to avoid a trade war that could slow global growth. Sky Network Television, Fisher & Paykel Healthcare and Spark NZ led broad-based gains. Orion Health jumped 11 per cent.
TME TRMEF FBU FCREY FRCEF SKT SYKWF PPSHY FBU TME SKKTY TDMEY SML
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to ASX:TME / TRADE ME GROUP LIMITED on message board site Silicon Investor.